Remove 2025 Remove Aortic Remove CMS
article thumbnail

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

CardiacWire

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B The post Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure appeared first on Cardiac Wire.

article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

Edwards has entered into an agreement to acquire JenaValve Technology , a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. A CMS national coverage determination is expected in early 2025.